Neurotech International Limited announced that the US Clinical Trial for its Mente Autism device has been completed andanalysis is underway. Principal Investigator for the Clinical Trial, Professor Frederick Carrick, advised that data collection for primary outcome measures for the neurofeedback study of Autism using the Mente Autism device (ClinicalTrials.gov ID: NCT02773303) has been completed and is duly noted at ClinicalTrials.gov, a resource provided by the U.S. National Library of Medicine. This is accessible at the following link. Preliminary findings of the Clinical Trial were presented at the 6th Cambridge International Conference on Mental Health Research 2017 held at Clare College, University of Cambridge, Cambridge, UK, held between 20 - 22 September 2017. As Professor Carrick noted, the preliminary findings "demonstrate[d] positive changes in children's neurological function after using the Mente Autism device in clinical study." The full announcement can be accessed at the following link. Investigators from the Carrick Institute have commenced compiling and analysing the data from the study in preparation for submission of their findings for publication. The final results of the study will not be available to Neurotech or the public until the investigation has been published. As a fully independent study, Neurotech has had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Neurotech looks forward to updating the market once results are available to it.